|
Gene: GART |
Gene summary for GART |
Gene summary. |
Gene information | Species | Human | Gene symbol | GART | Gene ID | 2618 |
Gene name | phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase | |
Gene Alias | AIRS | |
Cytomap | 21q22.11 | |
Gene Type | protein-coding | GO ID | GO:0003360 | UniProtAcc | P22102 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2618 | GART | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.70e-09 | 6.39e-01 | 0.294 |
2618 | GART | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.79e-04 | 1.10e+00 | 0.3487 |
2618 | GART | HTA11_99999965104_69814 | Human | Colorectum | MSS | 5.39e-07 | 7.51e-01 | 0.281 |
2618 | GART | HTA11_99999971662_82457 | Human | Colorectum | MSS | 9.06e-05 | 5.87e-01 | 0.3859 |
2618 | GART | A015-C-203 | Human | Colorectum | FAP | 2.34e-08 | -2.14e-01 | -0.1294 |
2618 | GART | A015-C-204 | Human | Colorectum | FAP | 1.52e-03 | -2.37e-01 | -0.0228 |
2618 | GART | A002-C-201 | Human | Colorectum | FAP | 9.32e-07 | -1.84e-01 | 0.0324 |
2618 | GART | A001-C-119 | Human | Colorectum | FAP | 3.41e-03 | -2.46e-01 | -0.1557 |
2618 | GART | A001-C-108 | Human | Colorectum | FAP | 1.18e-03 | -7.50e-02 | -0.0272 |
2618 | GART | A002-C-205 | Human | Colorectum | FAP | 5.21e-09 | -1.05e-01 | -0.1236 |
2618 | GART | A015-C-006 | Human | Colorectum | FAP | 1.66e-06 | -1.58e-01 | -0.0994 |
2618 | GART | A015-C-106 | Human | Colorectum | FAP | 2.69e-02 | -1.23e-01 | -0.0511 |
2618 | GART | A002-C-114 | Human | Colorectum | FAP | 7.42e-08 | -2.27e-01 | -0.1561 |
2618 | GART | A015-C-104 | Human | Colorectum | FAP | 2.21e-10 | -2.28e-01 | -0.1899 |
2618 | GART | A002-C-016 | Human | Colorectum | FAP | 5.82e-09 | -2.06e-01 | 0.0521 |
2618 | GART | A015-C-002 | Human | Colorectum | FAP | 2.05e-06 | -3.09e-01 | -0.0763 |
2618 | GART | A002-C-116 | Human | Colorectum | FAP | 5.72e-11 | -1.83e-01 | -0.0452 |
2618 | GART | A014-C-008 | Human | Colorectum | FAP | 8.97e-05 | -5.24e-02 | -0.191 |
2618 | GART | A018-E-020 | Human | Colorectum | FAP | 1.74e-09 | -2.50e-01 | -0.2034 |
2618 | GART | F034 | Human | Colorectum | FAP | 6.40e-06 | -1.15e-01 | -0.0665 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000675324 | Skin | cSCC | nucleoside phosphate metabolic process | 176/4864 | 497/18723 | 1.55e-06 | 2.62e-05 | 176 |
GO:0046390111 | Skin | cSCC | ribose phosphate biosynthetic process | 79/4864 | 190/18723 | 1.86e-06 | 3.10e-05 | 79 |
GO:000911724 | Skin | cSCC | nucleotide metabolic process | 173/4864 | 489/18723 | 2.03e-06 | 3.35e-05 | 173 |
GO:0072521112 | Skin | cSCC | purine-containing compound metabolic process | 150/4864 | 416/18723 | 2.88e-06 | 4.54e-05 | 150 |
GO:0009259112 | Skin | cSCC | ribonucleotide metabolic process | 138/4864 | 385/18723 | 1.00e-05 | 1.30e-04 | 138 |
GO:000912610 | Skin | cSCC | purine nucleoside monophosphate metabolic process | 25/4864 | 44/18723 | 1.40e-05 | 1.74e-04 | 25 |
GO:00091235 | Skin | cSCC | nucleoside monophosphate metabolic process | 37/4864 | 76/18723 | 1.75e-05 | 2.11e-04 | 37 |
GO:0006163112 | Skin | cSCC | purine nucleotide metabolic process | 140/4864 | 396/18723 | 1.93e-05 | 2.27e-04 | 140 |
GO:0009260111 | Skin | cSCC | ribonucleotide biosynthetic process | 73/4864 | 182/18723 | 2.01e-05 | 2.36e-04 | 73 |
GO:0009150112 | Skin | cSCC | purine ribonucleotide metabolic process | 131/4864 | 368/18723 | 2.42e-05 | 2.76e-04 | 131 |
GO:007252218 | Skin | cSCC | purine-containing compound biosynthetic process | 78/4864 | 200/18723 | 3.44e-05 | 3.74e-04 | 78 |
GO:190129310 | Skin | cSCC | nucleoside phosphate biosynthetic process | 95/4864 | 256/18723 | 5.21e-05 | 5.31e-04 | 95 |
GO:000916510 | Skin | cSCC | nucleotide biosynthetic process | 94/4864 | 254/18723 | 6.40e-05 | 6.25e-04 | 94 |
GO:0009152111 | Skin | cSCC | purine ribonucleotide biosynthetic process | 67/4864 | 169/18723 | 6.60e-05 | 6.43e-04 | 67 |
GO:00065758 | Skin | cSCC | cellular modified amino acid metabolic process | 73/4864 | 188/18723 | 7.11e-05 | 6.85e-04 | 73 |
GO:000616418 | Skin | cSCC | purine nucleotide biosynthetic process | 73/4864 | 191/18723 | 1.28e-04 | 1.17e-03 | 73 |
GO:00423987 | Skin | cSCC | cellular modified amino acid biosynthetic process | 24/4864 | 46/18723 | 1.32e-04 | 1.19e-03 | 24 |
GO:00091679 | Skin | cSCC | purine ribonucleoside monophosphate metabolic process | 22/4864 | 41/18723 | 1.46e-04 | 1.31e-03 | 22 |
GO:00091616 | Skin | cSCC | ribonucleoside monophosphate metabolic process | 28/4864 | 58/18723 | 2.14e-04 | 1.77e-03 | 28 |
GO:00091244 | Skin | cSCC | nucleoside monophosphate biosynthetic process | 22/4864 | 42/18723 | 2.31e-04 | 1.90e-03 | 22 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00670 | Colorectum | MSI-H | One carbon pool by folate | 7/797 | 20/8465 | 1.65e-03 | 1.73e-02 | 1.45e-02 | 7 |
hsa006701 | Colorectum | MSI-H | One carbon pool by folate | 7/797 | 20/8465 | 1.65e-03 | 1.73e-02 | 1.45e-02 | 7 |
hsa015232 | Esophagus | ESCC | Antifolate resistance | 22/4205 | 30/8465 | 7.23e-03 | 1.76e-02 | 8.99e-03 | 22 |
hsa0152311 | Esophagus | ESCC | Antifolate resistance | 22/4205 | 30/8465 | 7.23e-03 | 1.76e-02 | 8.99e-03 | 22 |
hsa006702 | Liver | HCC | One carbon pool by folate | 17/4020 | 20/8465 | 6.04e-04 | 2.50e-03 | 1.39e-03 | 17 |
hsa01523 | Liver | HCC | Antifolate resistance | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
hsa0067011 | Liver | HCC | One carbon pool by folate | 17/4020 | 20/8465 | 6.04e-04 | 2.50e-03 | 1.39e-03 | 17 |
hsa015231 | Liver | HCC | Antifolate resistance | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GART | SNV | Missense_Mutation | novel | c.2695N>A | p.Leu899Ile | p.L899I | P22102 | protein_coding | tolerated(0.07) | probably_damaging(0.987) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GART | SNV | Missense_Mutation | c.667G>C | p.Glu223Gln | p.E223Q | P22102 | protein_coding | deleterious(0.01) | benign(0.179) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GART | SNV | Missense_Mutation | c.1193N>T | p.Ser398Leu | p.S398L | P22102 | protein_coding | tolerated(0.39) | benign(0.011) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GART | SNV | Missense_Mutation | c.342N>A | p.Met114Ile | p.M114I | P22102 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GART | insertion | In_Frame_Ins | novel | c.1301_1302insCATACATATCCT | p.Ser434_Leu435insIleHisIleLeu | p.S434_L435insIHIL | P22102 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
GART | deletion | Frame_Shift_Del | c.3002delA | p.Asn1001MetfsTer14 | p.N1001Mfs*14 | P22102 | protein_coding | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
GART | deletion | Frame_Shift_Del | rs777845343 | c.2420delA | p.Lys807ArgfsTer7 | p.K807Rfs*7 | P22102 | protein_coding | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | ||
GART | SNV | Missense_Mutation | c.1237G>A | p.Glu413Lys | p.E413K | P22102 | protein_coding | tolerated(0.33) | benign(0.012) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
GART | SNV | Missense_Mutation | c.2488N>C | p.Glu830Gln | p.E830Q | P22102 | protein_coding | tolerated(0.26) | benign(0.006) | TCGA-JW-A852-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
GART | SNV | Missense_Mutation | c.763N>A | p.Leu255Ile | p.L255I | P22102 | protein_coding | tolerated(0.1) | probably_damaging(0.947) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2618 | GART | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1200373 | ||
2618 | GART | ENZYME, DRUGGABLE GENOME | PEMETREXED | PEMETREXED | ||
2618 | GART | ENZYME, DRUGGABLE GENOME | PELITREXOL | PELITREXOL | ||
2618 | GART | ENZYME, DRUGGABLE GENOME | LY309887 | |||
2618 | GART | ENZYME, DRUGGABLE GENOME | PEMETREXED | PEMETREXED | ||
2618 | GART | ENZYME, DRUGGABLE GENOME | AG2034 | |||
2618 | GART | ENZYME, DRUGGABLE GENOME | LOMETREXOL | LOMETREXOL | 22243528 |
Page: 1 |